老年性黄斑变性的药物治疗研究新进展
Progressions in medication of age-related macular degeneration
摘要
老年性黄斑变性是老年人的主要致盲眼病之一。近年来对老年性黄斑变性相关性脉络膜新生血管的药物治疗研究有了显著进展,在对抗血管内皮生长因子、人工合成的皮质激素、色素上皮源性因子、蛋白激酶C抑制剂、环氧化酶-2抑制剂、尿激酶纤溶酶原激活剂-受体系统抑制剂等药物的临床和实验研究取得了可喜的成果,尤其是抗血管内皮生长因子的各种药物的临床应用已显示明显疗效,为患者带来了复明的希望。
出处
《四川生理科学杂志》
2007年第3期131-134,共4页
Sichuan Journal of Physiological Sciences
参考文献21
-
1[1]Heier JS.Review of Lucentis(ranibizumab,rhuFab V2) phase I/II trial results:6-month treatment of exudative AMD[J].Invest Ophthalmol Vis Sci.2004;45:ARVO E-Abstract 1109 and paper discussion.
-
2[2]Eyetech Study Group.Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration:phase II study results[J].Ophthalmology.2003;110:979-986.
-
3[3]The Eyetech Study Group.Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration[J].Retina.2002;22:143 -152.
-
4[4]P van Wijngaarden.Inhibitors of ocular neovascularization:promises and potential problems[J].JAMA.2005;293:1509.
-
5[5]Carrasquillo KG,Ricker JA,Rigas IK,et al.Controlled delivery of the anti-VEGF aptamer EYE001 with poly (lactic-co-glycolic) acid microspheres[J].Invest Ophthalmol Vis Sci.2003;44:290-299.
-
6[6]Anecortave Acetate Study Group.Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration:twelve-month clinical outcomes[J].Ophthalmology.2003;110:2372-2383.
-
7[7]Ciulla TA,Criswell MH,Danis RP,et al.Squalamine lactate reduces choridal neovascularization in a laser-injury model in the rat.Retina,2003;23:808-814.
-
8[8]Higgins RD,Yan Y,Geng Y,et al.Reg ression of retinopathy by Squalamine in a mouse model[J].Pediatr Res.2004;56:144-149.
-
9[9]Garcia CA,Quiroz-Mercado H,Uwaydat S,et al.A phase I/II trial of intravenous squalamine lactate for treatment of choroidal neovascularization in age-related macular degeneration (ARMD)[J].Invest Ophthalmol Vis Sci.2004;45:ARVO E-Abstract 2362.
-
10[10]Mori K,Gehlbach P,Ando A,et al.Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor.Invest Ophthalmol Vis Sci.2002;43:2428-2434.
-
1邓淋曼,彭惠.miRNAs在年龄相关性黄斑变性的潜在作用[J].国际眼科杂志,2015,15(1):61-64. 被引量：4
-
2唐敏,张军军,范玮.补体调节蛋白与眼病[J].国际眼科杂志,2012,12(5):856-860. 被引量：1
-
3林颖.中医辨证治疗老年性黄斑变性视觉诱发电位变化的研究[J].中医临床研究,2012,4(23):1-4. 被引量：3
-
4舒凌,律鹏.低氧环境下HIF-1α与视网膜相关疾病的研究进展[J].高原医学杂志,2012,22(1):61-63.
-
5刘宏伟.干细胞技术让“老黄变”患者看到光明[J].保健医苑,2012(7):26-27.
-
6徐延山,杜蓓.老年性黄斑变性及治疗[J].开卷有益（求医问药）,2008(12):22-23.
-
7郭向明,张清炯.进一步重视和加强眼底病相关的基因研究[J].中华眼底病杂志,2006,22(2):73-74.
-
8高志强,韩宝惠.蛋白激酶C抑制剂与非小细胞肺癌的治疗[J].中国肺癌杂志,2009,12(1):68-72. 被引量：2
-
9黄镇华.针灸治疗青光眼临床研究进展[J].河北中医,2006,28(1):75-76.
-
10何贤辉,曾耀英,徐丽慧,孙荭,李振,狄静芳.蛋白激酶C抑制剂对T细胞表达IL-2及IFN-γ的影响[J].中国病理生理杂志,2002,18(5):522-525. 被引量：8
